Literature DB >> 28392556

Role of orexin-A in the ventrolateral preoptic area on components of total energy expenditure.

J E Coborn1, D P DePorter1, V Mavanji2, C M Sinton3, C M Kotz2,4,5,6, C J Billington2,5,6,7, J A Teske1,2,5,6.   

Abstract

BACKGROUND: Identifying whether components of total energy expenditure (EE) are affected by orexin receptor (OXR1 and OXR2) stimulation or antagonism with dual orexin receptor antagonists (DORAs) has relevance for obesity treatment. Orexin receptor stimulation reduces weight gain by increasing total EE and EE during spontaneous physical activity (SPA).
OBJECTIVE: The purpose of this study was to determine if a DORA (TCS-1102) in the ventrolateral preoptic area (VLPO) reduced orexin-A-induced arousal, SPA, total EE and EE during sleep, rest, wake and SPA and whether the DORA alone reduced total EE and its components. We hypothesized that: (1) a DORA would reduce orexin-A induced increases in arousal, SPA, components of total EE, reductions in sleep and the EE during sleep and (2) the DORA alone would reduce baseline (non-stimulated) SPA and total EE. SUBJECTS/
METHODS: Sleep, wakefulness, SPA and EE were determined after microinjection of the DORA (TCS-1102) and orexin-A in the VLPO of male Sprague-Dawley rats with a unilateral cannula targeted towards the VLPO. Individual components of total EE were determined based on time-stamped data.
RESULTS: The DORA reduced orexin-A-induced increases in arousal, SPA, total EE and EE during SPA, wake, rest and sleep 1 h post injection (P<0.05). Orexin-A significantly reduced sleep and significantly increased EE during sleep 1 h post injection (P<0.05). Furthermore, the DORA alone significantly reduced total EE, EE during sleep (NREM and REM) and resting EE 2 h post injection (P<0.05).
CONCLUSIONS: These data suggest that orexin-A reduces weight gain by stimulating total EE through increases in EE during SPA, rest and sleep. Residual effects of the DORA alone include decreases in total EE and EE during sleep and rest, which may promote weight gain.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28392556      PMCID: PMC6893852          DOI: 10.1038/ijo.2017.92

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  60 in total

1.  Effects of lateral preoptic area application of orexin-A on sleep-wakefulness.

Authors:  M M Methippara; M N Alam; R Szymusiak; D McGinty
Journal:  Neuroreport       Date:  2000-11-09       Impact factor: 1.837

2.  Neurones in the supraoptic nucleus of the rat are regulated by a projection from the suprachiasmatic nucleus.

Authors:  L N Cui; K Saeb-Parsy; R E Dyball
Journal:  J Physiol       Date:  1997-07-01       Impact factor: 5.182

3.  Identification of sleep-promoting neurons in vitro.

Authors:  T Gallopin; P Fort; E Eggermann; B Cauli; P H Luppi; J Rossier; E Audinat; M Mühlethaler; M Serafin
Journal:  Nature       Date:  2000-04-27       Impact factor: 49.962

4.  Acute partial sleep deprivation due to environmental noise increases weight gain by reducing energy expenditure in rodents.

Authors:  Jennifer B Parrish; Jennifer A Teske
Journal:  Obesity (Silver Spring)       Date:  2016-11-29       Impact factor: 5.002

5.  Activation of ventrolateral preoptic neurons during sleep.

Authors:  J E Sherin; P J Shiromani; R W McCarley; C B Saper
Journal:  Science       Date:  1996-01-12       Impact factor: 47.728

6.  Diffusion from an injected volume of a substance in brain tissue with arbitrary volume fraction and tortuosity.

Authors:  C Nicholson
Journal:  Brain Res       Date:  1985-05-06       Impact factor: 3.252

7.  Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity.

Authors:  J Hara; C T Beuckmann; T Nambu; J T Willie; R M Chemelli; C M Sinton; F Sugiyama; K Yagami; K Goto; M Yanagisawa; T Sakurai
Journal:  Neuron       Date:  2001-05       Impact factor: 17.173

8.  Sleep-waking discharge patterns of ventrolateral preoptic/anterior hypothalamic neurons in rats.

Authors:  R Szymusiak; N Alam; T L Steininger; D McGinty
Journal:  Brain Res       Date:  1998-08-24       Impact factor: 3.252

9.  Orexin A (hypocretin 1) injected into hypothalamic paraventricular nucleus and spontaneous physical activity in rats.

Authors:  Kohji Kiwaki; Catherine M Kotz; Chuanfeng Wang; Lorraine Lanningham-Foster; James A Levine
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-12-02       Impact factor: 4.310

10.  Mechanisms underlying obesity resistance associated with high spontaneous physical activity.

Authors:  J A Teske; C J Billington; C M Kotz
Journal:  Neuroscience       Date:  2013-10-22       Impact factor: 3.590

View more
  6 in total

1.  Orexin enhances neuronal synchronization in adult rat hypothalamic culture: a model to study hypothalamic function.

Authors:  Vijayakumar Mavanji; Apostolos P Georgopoulos; Catherine M Kotz
Journal:  J Neurophysiol       Date:  2022-03-30       Impact factor: 2.974

Review 2.  Spontaneous Physical Activity Defends Against Obesity.

Authors:  Catherine M Kotz; Claudio E Perez-Leighton; Jennifer A Teske; Charles J Billington
Journal:  Curr Obes Rep       Date:  2017-12

3.  Noise-induced sleep disruption increases weight gain and decreases energy metabolism in female rats.

Authors:  Jamie E Coborn; Rebecca E Lessie; Christopher M Sinton; Naomi E Rance; Claudio E Perez-Leighton; Jennifer A Teske
Journal:  Int J Obes (Lond)       Date:  2018-12-19       Impact factor: 5.095

4.  Inhibition of Orexin/Hypocretin Neurons Ameliorates Elevated Physical Activity and Energy Expenditure in the A53T Mouse Model of Parkinson's Disease.

Authors:  Milos Stanojlovic; Jean Pierre Pallais; Catherine M Kotz
Journal:  Int J Mol Sci       Date:  2021-01-14       Impact factor: 5.923

Review 5.  The Case for TAAR1 as a Modulator of Central Nervous System Function.

Authors:  Grazia Rutigliano; Alice Accorroni; Riccardo Zucchi
Journal:  Front Pharmacol       Date:  2018-01-10       Impact factor: 5.810

Review 6.  Orexins, Sleep, and Blood Pressure.

Authors:  Mariusz Sieminski; Jacek Szypenbejl; Eemil Partinen
Journal:  Curr Hypertens Rep       Date:  2018-07-10       Impact factor: 5.369

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.